Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;10(1):143-165.
doi: 10.1007/s40487-021-00181-1. Epub 2022 Jan 13.

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

Chirag Desai  1 , Ashok K Vaid  2 , Ghanashyam Biswas  3 , Sandeep Batra  4 , Palanki S Dattatreya  5 , Prabrajya Narayan Mohapatra  6 , Deepak Dabkara  7 , Adwaita Gore  8 , Sagar B Bhagat  9 , Saiprasad Patil  10 , Hanmant Barkate  10
Affiliations

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

Chirag Desai et al. Oncol Ther. 2022 Jun.

Abstract

Introduction: With the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India.

Methods: An expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of ≥ 7 with 1 outlier were considered as "consensus."

Results: Degarelix was the preferred androgen deprivation therapy (ADT). While ADT plus docetaxel was the preferred option for metastatic castrate-sensitive/naïve prostate cancer patients with high-volume disease, ADT with abiraterone was the preferred choice for low-volume disease. Docetaxel was the preferred first-line treatment option in men who received ADT alone in the castrate-sensitive/naïve setting. For patients progressing on or after docetaxel for metastatic castrate-resistant prostate cancer (without prior abiraterone or enzalutamide), the experts reached a consensus on the use of enzalutamide as the preferred second-line treatment option. No consensus was reached for the third-line treatment options.

Conclusion: This article is intended to serve as a guide to help clinicians discuss with their patients as part of the shared and multidisciplinary decision-making for improved APC management in India.

Keywords: Advanced prostate cancer; Androgen deprivation therapy; Castrate-resistant prostate cancer; Castrate-sensitive prostate cancer; Consensus; Delphi; India.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Steps followed in the modified Delphi method
Fig. 2
Fig. 2
Sequencing of therapy for APC based on expert consensus
See this image and copyright information in PMC

References

    1. Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, et al. Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol Oncol. 2020;13(1):144. doi: 10.1186/s13045-020-00978-z. - DOI - PMC - PubMed
    1. Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced prostate cancer: treatment advances and future directions. Trends Cancer. 2020;6(8):702–715. doi: 10.1016/j.trecan.2020.04.010. - DOI - PubMed
    1. Murthy V, Mallick I, Arunsingh M, Gupta P. Prostate radiotherapy in India: evolution, practice and challenges in the 21st century. Clin Oncol (R Coll Radiol) 2019;31(8):492–501. doi: 10.1016/j.clon.2019.05.020. - DOI - PubMed
    1. GlOBOCAN 2020. India. Available at: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=27&single_unit=5.... Accessed on 15 Feb 2021.
    1. Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017;35:S1–S13. doi: 10.1016/j.urolonc.2017.01.020. - DOI - PubMed

LinkOut - more resources